On April 27, Huahui Anjian announced that it had entered into a global exclusive option, licensing and collaboration agreement with BeiGene for the novel tumor immunotherapy trispecific antibody HH160 , granting BeiGene an exclusive option involving the development, production and commercialization of the product.

Under the agreement, BeiGene will pay Huahui Anjian an upfront payment of US$20 million. Huahui Anjian is entitled to an additional US$100 million exercise payment if BeiGene exercises its option. Upon achieving development and regulatory milestones, Huahui Anjian is entitled to payments of up to US$374 million. Upon achieving sales milestones, Huahui Anjian is entitled to payments of up to US$1.53 billion, and is also entitled to tiered licensing fees.
In addition, both parties will actively negotiate and discuss BeiGene's potential participation in Huahui Anjian's financing, and the specific transaction terms and details will be determined through further negotiation.
HH160 is a novel trispecific antibody developed by Huahui Anjian using its proprietary PolyBoost™ multispecific antibody platform. HH160 simultaneously targets three clinically validated tumor immunotherapy and anti-angiogenic targets: PD-1, CTLA-4, and VEGF-A. This synergistic three-pronged approach is expected to enhance efficacy, achieve tumor-specific drug distribution, and reduce treatment-related side effects.

https://mp.weixin.qq.com/s/uTn-o1OEnlEsw1TGLhUnGA